[go: up one dir, main page]

WO2006126214A3 - Nouvelles compositions injectables et procede de preparation desdites compositions - Google Patents

Nouvelles compositions injectables et procede de preparation desdites compositions Download PDF

Info

Publication number
WO2006126214A3
WO2006126214A3 PCT/IN2006/000177 IN2006000177W WO2006126214A3 WO 2006126214 A3 WO2006126214 A3 WO 2006126214A3 IN 2006000177 W IN2006000177 W IN 2006000177W WO 2006126214 A3 WO2006126214 A3 WO 2006126214A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
painful
pain
inflammatory
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000177
Other languages
English (en)
Other versions
WO2006126214A2 (fr
Inventor
Rajesh Jain
Kour Chand Jindal
Sukhjeet Singh
Sanjay Boldhane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0611170-0A priority Critical patent/BRPI0611170A2/pt
Priority to EP06756263A priority patent/EP1895983A2/fr
Priority to MX2007014862A priority patent/MX2007014862A/es
Priority to JP2008513009A priority patent/JP2008542260A/ja
Priority to CA002609242A priority patent/CA2609242A1/fr
Priority to RSP-2007/0461A priority patent/RS20070461A/sr
Priority to EA200702646A priority patent/EA200702646A1/ru
Priority to AU2006250765A priority patent/AU2006250765A1/en
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of WO2006126214A2 publication Critical patent/WO2006126214A2/fr
Publication of WO2006126214A3 publication Critical patent/WO2006126214A3/fr
Anticipated expiration legal-status Critical
Priority to NO20076468A priority patent/NO20076468L/no
Priority to TNP2007000482A priority patent/TNSN07482A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques injectables, nouvelles et hautement stables, qui comprennent au moins un inhibiteur de la cyclooxygénase-II (COX-II) ou un anti-inflammatoire non stéroïdien (AINS) ou un inhibiteur de COX/LOX ou leurs formes tautomères, analogues, isomères, polymorphes, solvates, promédicaments ou sels de ces derniers comme principe actif approprié à une administration parentérale, de préférence, par voie intramusculaire (IM) ou intraveineuse (IV). L'invention concerne également un procédé de préparation de ces compositions et des méthodes thérapeutiques d'utilisation de ces compositions. Les compositions injectables analgésiques et anti-inflammatoires selon l'invention sont très utiles chez les mammifères, notamment les humains, pour le traitement d'états douloureux aigus tels qu'un ou plusieurs des états suivants : traumatismes postopératoires, douleur associée au cancer, blessures de sport, migraine, douleur neurologique et douleur associée à la sciatique et à la spondylarthrite et à des maladies analogues et/ou des états de douleur chronique et/ou divers états inflammatoires douloureux, tels que la douleur postopératoire, la dysménorrhée primaire et l'arthrose douloureuse, et/ou d'autres troubles associés, tels que l'inflammation, la fièvre, l'allergie ou des états analogues.
PCT/IN2006/000177 2005-05-27 2006-05-25 Nouvelles compositions injectables et procede de preparation desdites compositions Ceased WO2006126214A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EA200702646A EA200702646A1 (ru) 2005-05-27 2006-05-25 Композиции для инъекций и способ приготовления данных композиций
MX2007014862A MX2007014862A (es) 2005-05-27 2006-05-25 Composiciones inyectables y procedimiento para la preparacion de dichas composiciones.
JP2008513009A JP2008542260A (ja) 2005-05-27 2006-05-25 新規の注射可能組成物及びその調製方法
CA002609242A CA2609242A1 (fr) 2005-05-27 2006-05-25 Nouvelles compositions injectables et procede de preparation desdites compositions
RSP-2007/0461A RS20070461A (sr) 2005-05-27 2006-05-25 Injektibilne kompozicije i postupak za njihovo dobijanje
BRPI0611170-0A BRPI0611170A2 (pt) 2005-05-27 2006-05-25 composições injetáveis e processo para o preparo de tais composições
EP06756263A EP1895983A2 (fr) 2005-05-27 2006-05-25 Nouvelles compositions injectables et procede de preparation desdites compositions
AU2006250765A AU2006250765A1 (en) 2005-05-27 2006-05-25 Injectable compositions and process for preparation of such compositions
NO20076468A NO20076468L (no) 2005-05-27 2007-12-14 Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger
TNP2007000482A TNSN07482A1 (fr) 2005-05-27 2007-12-21 Nouvelles compositions injectables et procede de preparation desdites compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1357/DEL/2005 2005-05-27
IN1357DE2005 2005-05-27

Publications (2)

Publication Number Publication Date
WO2006126214A2 WO2006126214A2 (fr) 2006-11-30
WO2006126214A3 true WO2006126214A3 (fr) 2007-06-07

Family

ID=36917368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000177 Ceased WO2006126214A2 (fr) 2005-05-27 2006-05-25 Nouvelles compositions injectables et procede de preparation desdites compositions

Country Status (15)

Country Link
EP (1) EP1895983A2 (fr)
JP (1) JP2008542260A (fr)
KR (1) KR20080016689A (fr)
CN (1) CN101217939A (fr)
AU (1) AU2006250765A1 (fr)
BR (1) BRPI0611170A2 (fr)
CA (1) CA2609242A1 (fr)
CR (1) CR9616A (fr)
EA (1) EA200702646A1 (fr)
MX (1) MX2007014862A (fr)
NO (1) NO20076468L (fr)
RS (1) RS20070461A (fr)
TN (1) TNSN07482A1 (fr)
WO (1) WO2006126214A2 (fr)
ZA (1) ZA200711068B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447065B2 (en) 2011-10-18 2016-09-20 Raqualia Pharma Inc. Pharmaceutical composition

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200650B1 (fr) 2007-09-07 2016-01-06 United Therapeutics Corporation Tampons présentant une activité bactéricide sélective contre les bactéries à gram négatif et leurs procédés d'utilisation
JP2012523377A (ja) 2009-03-12 2012-10-04 カンバーランド ファーマスーティカルズ インコーポレイテッド 静脈内イブプロフェンの投与
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
CN102335114B (zh) * 2010-07-23 2015-07-15 重庆医药工业研究院有限责任公司 一种稳定的布洛芬精氨酸注射剂及其制备方法
CN102370615B (zh) * 2010-08-19 2013-09-04 四川科伦药物研究有限公司 一种布洛芬注射制剂及其制备方法
CN102512383A (zh) * 2011-12-25 2012-06-27 天津市嵩锐医药科技有限公司 供注射用的帕瑞昔布钠药物组合物
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
CN103372216B (zh) * 2012-04-26 2015-05-06 北京京卫燕康药物研究所有限公司 一种含有塞来昔布的固体药物组合物
US20140187635A1 (en) * 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac compositions
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN103263385B (zh) * 2013-05-17 2016-04-27 江苏正大清江制药有限公司 一种塞来昔布长效纳米注射剂及其制备方法
PH12017501005B1 (en) * 2014-12-20 2024-03-27 Troikaa Pharmaceuticals Ltd Injectable formulations of paracetamol
WO2016170401A1 (fr) * 2015-04-20 2016-10-27 Umedica Laboratories Pvt. Ltd Nouvelle composition injectable de diclofénac sodique
CN107303264A (zh) * 2016-04-18 2017-10-31 重庆润泽医药有限公司 无泡沫左旋奥拉西坦注射液及其制备方法
CN107303266B (zh) * 2016-04-18 2020-09-08 重庆润泽医药有限公司 左旋奥拉西坦注射液及其制备方法
FR3077984B1 (fr) * 2018-02-16 2020-02-21 Vetoquinol Sa Composition multiusage de torasemide
CN109498852B (zh) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 治疗骨科疾病的生物降解材料及其应用
CN111103381A (zh) * 2019-12-25 2020-05-05 南京希麦迪医药科技有限公司 一种液质联用测定人血浆中尼美舒利浓度的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595766A1 (fr) * 1992-10-22 1994-05-04 Ciba-Geigy Ag Solutions à usage parenteral contenant des sels du diclofenac
EP0795329A1 (fr) * 1996-03-15 1997-09-17 PULITZER ITALIANA S.r.l. Solutions parentérales injectables contenant le piroxicam
US6451302B1 (en) * 1998-01-12 2002-09-17 Panacea Biotec Limited Parenteral water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs
US20030078266A1 (en) * 2001-04-03 2003-04-24 Kararli Tugrul T. Reconstitutable parenteral composition
WO2004014431A1 (fr) * 2002-08-12 2004-02-19 Ranbaxy Laboratories Limited Forme posologique parenterale d'inhibiteurs cox-2 selectifs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595766A1 (fr) * 1992-10-22 1994-05-04 Ciba-Geigy Ag Solutions à usage parenteral contenant des sels du diclofenac
EP0795329A1 (fr) * 1996-03-15 1997-09-17 PULITZER ITALIANA S.r.l. Solutions parentérales injectables contenant le piroxicam
US6451302B1 (en) * 1998-01-12 2002-09-17 Panacea Biotec Limited Parenteral water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs
US20030078266A1 (en) * 2001-04-03 2003-04-24 Kararli Tugrul T. Reconstitutable parenteral composition
WO2004014431A1 (fr) * 2002-08-12 2004-02-19 Ranbaxy Laboratories Limited Forme posologique parenterale d'inhibiteurs cox-2 selectifs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447065B2 (en) 2011-10-18 2016-09-20 Raqualia Pharma Inc. Pharmaceutical composition

Also Published As

Publication number Publication date
JP2008542260A (ja) 2008-11-27
RS20070461A (sr) 2008-11-28
KR20080016689A (ko) 2008-02-21
ZA200711068B (en) 2009-03-25
BRPI0611170A2 (pt) 2010-08-17
NO20076468L (no) 2008-02-27
WO2006126214A2 (fr) 2006-11-30
CR9616A (es) 2008-10-30
TNSN07482A1 (fr) 2009-03-17
EA200702646A1 (ru) 2008-06-30
CN101217939A (zh) 2008-07-09
AU2006250765A1 (en) 2006-11-30
EP1895983A2 (fr) 2008-03-12
MX2007014862A (es) 2008-02-21
CA2609242A1 (fr) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2006126214A3 (fr) Nouvelles compositions injectables et procede de preparation desdites compositions
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
WO2008074997A8 (fr) Benzamides de pyridine et benzamides de pyrazine utilisés en tant qu'inhibiteurs de la pkd
WO2008024978A3 (fr) Dérivés de benzène, de pyridine et de pyridazine
WO2009025763A3 (fr) Composition thérapeutique pour le traitement de l'inflammation des annexes et des tissus oculaires
WO2009029622A3 (fr) Médicaments antiviraux pour le traitement d'une infection par arénavirus
SG11201808167VA (en) Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CL2007003263A1 (es) Compuestos derivados de 1,4-benzotiepina 1,1-dioxido; producto farmaceutico; procedimiento de preparacion; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, e
WO2008033455A3 (fr) Dérivés de biphényle et hétéroarylphényle
NZ601788A (en) Inhibitors of nicotinamide phosphoribosyltransferase and therapeutic uses thereof
WO2007005668A3 (fr) Inhibiteurs de bis-aryl kinase et methode associee
BRPI0707401B8 (pt) compostos inibidores de cinase, composição farmacêutica, processo para a preparação e usos dos referidos compostos ou de um pró-fármaco de um composto
WO2008052671A3 (fr) Thérapie combinatoire à base d'oxazolidinone substituée
WO2008008474A3 (fr) Compositions et procédés de traitement des cas de douleur chronique
WO2005002582A3 (fr) Composes actifs de trp-p8 et methodes de traitement therapeutique
WO2007048070A3 (fr) Composés et méthodes d'utilisation
WO2005035485A3 (fr) Composes analgesiques, leur synthese, et compositions pharmaceutiques les contenant
WO2016178092A8 (fr) Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
EP2215054B8 (fr) Dérivés amide à titre de ligands des canaux ioniques et compositions pharmaceutiques et procédés d'utilisation correspondants
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
DK1781596T3 (da) Aminosyreafledte profarmaka af propofolsammensætninger og anvendelser deraf
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
WO2010042500A3 (fr) Inhibiteurs de la protéine de choc thermique 90, leurs procédés de préparation et leurs procédés d'utilisation
UY29790A1 (es) Sales de diariloimidazola-4-carboxamidas, composiciones que las contienen, procesos de preparación y aplicaciones
WO2008024970A3 (fr) Dérivés de benzène, de pyridine et de pyridazine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2609242

Country of ref document: CA

Ref document number: 563613

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014862

Country of ref document: MX

Ref document number: P-2007/0461

Country of ref document: RS

Ref document number: 2008513009

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006250765

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006756263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2007-009616

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200702646

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 07136818

Country of ref document: CO

Ref document number: 1020077030585

Country of ref document: KR

Ref document number: KR

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200680025093.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2006250765

Country of ref document: AU

Date of ref document: 20060525

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006250765

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006756263

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0611170

Country of ref document: BR

Kind code of ref document: A2